Innovative Diagnostic Platform Telo Genomics specializes in advanced telomere analysis and liquid biopsy technologies for oncology and neurological diseases, providing an opportunity to offer tailored diagnostic tools and services to hospitals, clinics, and research institutions focused on cancer and neurodegenerative conditions.

Growing Clinical Evidence With over 150 peer-reviewed publications and 25 clinical studies involving more than 3,000 patients, Telo Genomics’s solutions are backed by significant scientific validation, making them attractive for medical centers seeking proven prognostic and diagnostic tests.

Leadership and Strategic Expansion Recent appointments of new CEO and CFO indicate strategic leadership focused on growth, presenting sales opportunities in expanding partnership networks, clinical collaborations, and potential government or institutional funding programs.

Event Participation and Visibility Active engagement in prestigious conferences such as the American Society of Hematology and the International Myeloma Society suggests ongoing focus on increasing market awareness and establishing credibility with key medical and research stakeholders.

Market Growth Potential Positioned within a burgeoning liquid biopsy and personalized medicine space, Telo Genomics offers scalable solutions with a strong emphasis on oncology and neurodegenerative diseases, presenting significant sales opportunities as demand for less invasive diagnostic options continues to rise.